- You can view the full Gilead Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Gilead ( GILD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.3%. By the end of trading, Gilead fell $2.22 (-3.1%) to $70.01 on heavy volume. Throughout the day, 24,958,934 shares of Gilead exchanged hands as compared to its average daily volume of 13,766,700 shares. The stock ranged in price between $69.28-$71.71 after having opened the day at $71.71 as compared to the previous trading day's close of $72.23. Other companies within the Drugs industry that declined today were: Ohr Pharmaceutical ( OHRP), down 18.2%, Sorrento Therapeutics ( SRNE), down 16.5%, Galmed Pharmaceuticals ( GLMD), down 9.4% and Bacterin International Holdings ( BONE), down 9.3%. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $111.0 billion and is part of the health care sector. Shares are down 3.8% year to date as of the close of trading on Monday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 1 rates it a hold. TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
